Multiple Myeloma
Advertisement
Higher creatinine levels and decompression surgery without fusion were linked to complications after spinal surgery in MM.
The phase 1/2 MajesTEC-1 study established a recommended dose for subcutaneous teclistamab in relapsed or refractory MM.
Prior allogeneic stem cell transplantation did not appear to impact the safety and efficacy of cilta-cel treatment for MM.
IMWG multiple myeloma treatment guidelines informed by studies with a major lack of Black patients, study finds.
Daratumumab added to carfilzomib-lenalidomide-dexamethasone triplet therapy for multiple myeloma improved MRD and survival.
Age, marital status, and tumor site were independent prognostic factors for extramedullary multiple myeloma.
BMI before and at MM diagnosis did not significantly impact survival.
An educational intervention increased provider confidence in aligning multiple myeloma treatment decisions.
Elotuzumab combination therapy had promising activity and tolerability for patients with multiple myeloma in first relapse.
Selinexor-based triplet regimens were effective in patients with multiple myeloma who were refractory to anti-CD38 therapies.
Patients with multiple myeloma who are treated at academic centers have significantly improved survival rates.
Normal neutrophil levels may be lower for Black versus whites, leading to disparity in multiple myeloma trial enrollment,
Higher-dose cyclophosphamide worsened overall survival and platelet recovery in patients with MM undergoing CAR-T therapy.
Cilta-cel showed reduced disease progression and death versus standard care in patients with lenalidomide-refractory MM.
Direct oral anticoagulants were non-inferior to low-molecular-weight heparin for preventing VTE in patients with MM.
Radiation therapy neither improved nor halted neurologic deterioration in patients with spinal cord compression due to MM.
Based on meta-analysis, researchers reported β2 microglobulin level may predict thrombosis in patients with multiple ...
Study finds upregulation of CD138+ plasma miR-25 is significantly common and predicts poor treatment response in MM.
Researchers supported the use of D-VTd over VRd for induction therapy in multiple myeloma after comparing outcome data.
Predictive model flags patients with multiple myeloma that have increased risk of cardiovascular adverse events.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.